TrialClinical cancer research : an official journal of the American Association for Cancer Research2014

Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.

Alana A Kennedy-Nasser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.